Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision

Published on 10/04/2026 at 17:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inovio Pharmaceuticals stock fell to USD 1.16 on October 2, while the FDA targets October 30 for its INO-3107 decision. Q2 diluted EPS was a USD 0.07 loss versus a USD 0.22 consensus loss.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals stock (ISIN US45773H4092) fell 4.13 percent to USD 1.16 on Nasdaq on October 2, 2026, leaving the shares between a 52-week low of USD 0.56 and a high of USD 2.72. The next major company date is the FDA's October 30 target decision on INO-3107, the lead candidate for recurrent respiratory papillomatosis.

FDA decision sets the next test

According to Yahoo Finance in the August 12, 2026 earnings call, Inovio said the FDA had completed its late-cycle review meeting and all scheduled pre-licensure inspections for the INO-3107 application. Management also said the company was preparing for a potential launch while the review continued.

The regulatory outcome matters because INO-3107 is the company's lead clinical asset rather than a marketed product. Inovio describes its broader platform as DNA medicines supported by CELLECTRA delivery devices, with programs spanning HPV-related disease, cancer and infectious disease, according to its Inovio investor-relations page.

Quarterly loss narrows sharply

Inovio reported a Q2 2026 diluted loss of USD 0.07 per share, compared with a consensus loss of USD 0.22 per share, according to MarketBeat. The USD 0.15 per-share difference makes the quarterly result a meaningful comparison, even though the company remained loss-making.

The same Q2 call placed operating expenses at USD 18.6 million, down 19 percent from USD 23.1 million in Q2 2025. Inovio also reported USD 6.0 million of net loss for Q2 2026 versus USD 23.5 million in Q2 2025, while cash and short-term investments stood at USD 36.7 million at June 30, 2026, according to Yahoo Finance.

Consensus target stays above USD 3

Analyst expectations remain materially above the October 2 share price. MarketBeat reports a Moderate Buy consensus from eight analysts, including five Buy ratings, one Strong Buy, one Hold and one Sell. The average 12-month price target is USD 3.17, with a high of USD 4.00 and a low of USD 2.50.

At USD 1.16, the stock was 63.4 percent below the average target, using the same USD currency. The gap reflects the market's dependence on the INO-3107 decision, while the 52-week range shows that the shares have also traded well above the October 2 level.

Inovio Pharmaceuticals stock remains below yearly high

Inovio Pharmaceuticals stock closed at USD 1.16 on Nasdaq on October 2, 2026, with volume of 2,901,502 shares and a session range of USD 1.16 to USD 1.23.